Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Daniel P. van Kammen"'
Autor:
Nathan Goodman, David Craufurd, Josef Priller, Clement T. Loy, Daniel P. van Kammen, Mary Edmondson, LaVonne Goodman, Karen E. Anderson, Erik van Duijn, Carolyn Drazinic
Publikováno v:
Journal of Huntington's Disease
Anderson, K E, Van Duijn, E, Craufurd, D, Drazinic, C, Edmondson, M, Goodman, N, Van Kammen, D, Loy, C, Priller, J & Goodman, L V 2018, ' Clinical Management of Neuropsychiatric Symptoms of Huntington Disease : Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders ', Journal of Huntington's Disease, vol. 7, no. 3, pp. 239-250 . https://doi.org/10.3233/JHD-180293
Anderson, K E, Van Duijn, E, Craufurd, D, Drazinic, C, Edmondson, M, Goodman, N, Van Kammen, D, Loy, C, Priller, J & Goodman, L V 2018, ' Clinical Management of Neuropsychiatric Symptoms of Huntington Disease : Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders ', Journal of Huntington's Disease, vol. 7, no. 3, pp. 239-250 . https://doi.org/10.3233/JHD-180293
Background In clinical practice, several strategies and pharmacological options are available to treat neuropsychiatric symptoms of Huntington disease (HD). However, there is currently insufficient data for evidence-based guidelines on the management
Autor:
Daniel P. van Kammen, Herbert Y. Meltzer, Kimberly E. Vanover, David M. Weiner, Helio Elkis, Uli Hacksell, Perry Peters
Publikováno v:
Schizophrenia Research. 141(2-3):144-152
Most atypical antipsychotic drugs (APDs), e.g. risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT)2A than dopamine (DA) D2 receptors. This distinguishes them from typical APDs, e.g. haloperidol (HAL). Our objective was to tes
Autor:
Aileen K Ho, G. Bernhard Landwehrmeyer, J Giuliano, Ralf Reilmann, Jane S. Paulsen, Daniel P. van Kammen, John H. Warner, Beth Borowsky, Peter Kupchak, Kevin M. Biglan, Terrence Sills, Karen E. Anderson, Anthony L. Vaccarino, Andrew W. Michell, Christopher Kennard, Kenneth R. Evans, Mark Guttman
Publikováno v:
Europe PubMed Central
PLoS Currents
PLoS Currents
The Functional Rating Scale Taskforce for pre-Huntington Disease (FuRST-pHD) is a multinational, multidisciplinary initiative with the goal of developing a data-driven, comprehensive, psychometrically sound, rating scale for assessing symptoms and fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897dc06e3c9f93ca322aa27e7fd76c8e
https://ora.ox.ac.uk/objects/uuid:b09b0d51-f253-4ba8-b0d8-ed2d5a35a32c
https://ora.ox.ac.uk/objects/uuid:b09b0d51-f253-4ba8-b0d8-ed2d5a35a32c
Autor:
Kevin Duff, J Giuliano, Terrence Sills, Michael Orth, Karen E. Anderson, Mark Guttman, Kenneth R. Evans, Jane S. Paulsen, Beth Borowsky, Aileen K Ho, Daniel P. van Kammen, Anthony L. Vaccarino
Publikováno v:
Movement Disorders. 26:877-884
Although the Unified Huntington's Disease Rating Scale (UHDRS) is widely used in the assessment of Huntington disease (HD), the ability of individual items to discriminate individual differences in motor or behavioral manifestations has not been exte
Autor:
David M. Weiner, Sonia Ancoli-Israel, Kimberly E. Vanover, Robert E. Davis, Daniel P. van Kammen
Publikováno v:
Sleep Medicine. 12:134-141
Objective Determine the effects of pimavanserin tartrate [ACP-103; N -(4-flurophenylmethyl)- N -(1-methylpiperidin-4-yl)- N ′-(4-(2-methylpropyloxy)phenylmethyl)carbamide], a selective serotonin 5-HT 2A receptor inverse agonist, on slow wave sleep
Autor:
Lingjun Zuo, Joel Gelernter, Xingguang Luo, Henry R. Kranzler, Joseph Erdos, Lingeng Lu, Joyce A. Cramer, John H. Krystal, Robert A. Rosenheck, Daniel P. van Kammen, Dennis S. Charney
Publikováno v:
Psychiatric Genetics. 19:292-304
Background Straub et al. (2002b) located a susceptibility region for schizophrenia at the DTNBP1 locus. At least 40 studies (including one study in US populations) attempted to replicate this original finding, but the reported findings are highly div
Publikováno v:
Schizophrenia Research. 105:188-196
Longitudinal analysis is crucial in determining the ability of new interventions to successfully reduce negative symptoms in schizophrenia. However, there are still conflicting reports as to whether there are significant treatment effects on these sy
Autor:
Daniel P. van Kammen, David M. Weiner, Darren Wilbraham, Robert E. Davis, Timothy Mant, Kimberly E. Vanover, Doris Robbins-Weilert
Publikováno v:
The Journal of Clinical Pharmacology. 47:915-919
Autor:
Henry R. Kranzler, Daniel P. van Kammen, Xingguang Luo, Joseph Erdos, Jaakko Lappalainen, Joel Gelernter, Lingjun Zuo, Dennis S. Charney, Robert A. Rosenheck
Publikováno v:
American Journal of Medical Genetics. :25-30
Calcyon is a brain-specific D1 dopamine receptor-interacting protein, with a potential role in D1-mediated physiological processes, including motor control, reward mechanisms, and cognitive processes. Our objective was to investigate the relationship